Today: 1 July 2026
Browse Category

NZX:MEL 16 November 2025 - 29 April 2026

New Zealand Stock Market Today: NZX 50 Scrapes Out Gain as Fisher & Paykel Keeps Shares Afloat

New Zealand Stock Market Today: NZX 50 Scrapes Out Gain as Fisher & Paykel Keeps Shares Afloat

Wednesday saw the New Zealand stock market inch up, as the S&P/NZX 50 managed a slight gain, barely making it into the green. Fisher & Paykel Healthcare, along with the power sector, did enough to counter declines in travel, retail, and dairy shares. It wasn’t a big move, but with a softer tone across the rest of the board and recent pressure on the local benchmark, it counted. The index clawed back 5.901 points to finish at 12,770.300, after dropping 0.86% in the last session. According to Investing.com, 28.78 million shares changed hands on the day. The market started at 12,764.40 and slipped to 12,726.35 at its lowest.
29 April 2026
·····
New Zealand Stock Market Outlook for 4 December 2025: 10 Things to Know Before the NZX Opens

New Zealand Stock Market Outlook for 4 December 2025: 10 Things to Know Before the NZX Opens

The New Zealand sharemarket heads into Thursday’s open on the back of a two‑day rally, a fresh Fonterra update, and growing optimism that global central banks are done with aggressive tightening. Here’s a detailed look at what’s likely to shape trading on Thursday, 4 December 2025. Below, we unpack the moving parts.
3 December 2025
······
New Zealand Sharemarket Today: NZX 50 Slides 0.5% as Infratil Sell‑Off Caps Mainfreight Rally (13 November 2025)

New Zealand Sharemarket Today (17 November 2025): Black Pearl Returns, Comvita Deal Collapses, Warehouse Cost Reset in Focus

New Zealand’s stock market heads into Monday’s session under a cloud of caution after a sharp end‑of‑week sell‑off and a flurry of corporate announcements that could drive stock‑specific volatility through the day. On Friday, the S&P/NZX 50 Index fell 133.41 points, or 0.98%, to close at 13,464.46, with 106 decliners and just 34 gainers, as local investors followed Wall Street’s worst day in a month.Good Returns+1 Heavyweights such as Mainfreight, Infratil, Fisher & Paykel Healthcare and Meridian all eased, while smaller cap Comvita slumped after uncertainty over its takeover deal.Good Returns
16 November 2025
·······

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) leans on vertical integration for expansion push
    July 1, 2026, 8:14 AM EDT. Telix Pharmaceuticals (ASX:TLX) reported more commercial momentum and wider global footprint in radiopharmaceuticals on a June 2026 call. Management is focused on vertical integration, controlling its own manufacturing and distribution, to get a lasting edge in precision oncology. Its deal with Regeneron adds to a string of partnerships, but the company still faces pricing pressure and regulatory hurdles. Telix forecasts revenue of A$1.2 billion and A$81.9 million in earnings by 2029, about 37% above the current share price. Profitability could remain under strain as R&D and buildout costs stay high, and investors are told to be mindful of these risks against growth plans and pipeline deals.
Go toTop